The initial success of the copyright undeniably reshaped the drug landscape, but investing in companies primarily reliant on off-patent versions presents a challenging picture. While early earnings were impressive, the expiration of patents and the rise of cheaper alternatives have diminished the customer base. Therefore, a thorough assessment of o